Crispr Therapeutics: Poised For A Major Turnaround [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
Follow Summary Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline. Despite competition, Crispr's first-mover advantage, strategic partnerships, and robust pipeline create a durable moat, making it a compelling investment in the biotech sector. koto_feja Thesis CRISPR Therapeutics ( NASDAQ: CRSP ) is the market leader in transformative therapies incorporating CRISPR/Cas9 biotechnology, and their 9-year ongoing partnership with Vertex Pharmaceuticals ( VRTX ) brings great promise. Most recently, both companies rec
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]Yahoo! Finance
- Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? [Yahoo! Finance]Yahoo! Finance
- 3 Monster Stocks in the Making [Yahoo! Finance]Yahoo! Finance
- Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- The Gene Revolution: Transforming Lives through Gene Editing Therapeutics [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 11/13/24 - Form 4
- 11/12/24 - Form 144
- 11/5/24 - Form 10-Q
- CRSP's page on the SEC website